Chandrikha Chandrasekharan is an Oncology physician. OpenAlex indexes 84 publications with 435 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304000
Telephone
713-792-6161Provider last certified this registry record 3 Feb 2025.
Clinical trials
- Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
Sponsor: University of Iowa
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20257 payments
- Exelixis Inc.Program year20246 payments
- Curium US LLCProgram year20245 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
33.2%Serotonin-3 Receptor Antagonist15.1%Ondansetron Hcl100%Part D≥41 patientsAntidiarrheal microorganisms7.2%Creon100%Part D<11 patients+ 3 more classes in this area
Sensory organs
32.3%Corticosteroid32.3%Dexamethasone100%Part D≥35 patientsNervous system
24.4%Phenothiazine13%Prochlorperazine Maleate100%Part D≥38 patientsOpioid Agonist8.6%Oxycodone Hcl68%Hydromorphone Hcl32%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Molecular and immune landscape of early-onset versus average-onset well-differentiated enteropancreatic neuroendocrine tumors.
Journal of Clinical Oncology
2026 - Grade progression and high-grade transformation in neuroendocrine neoplasms
Endocrine Related Cancer
2026 - Risk Factors and Prognosis of Peritoneal Metastases in Small Bowel Neuroendocrine Tumor Patients
Annals of Surgical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”